Published in Biochem Pharmacol on March 01, 2002
Adenosine receptors as therapeutic targets. Nat Rev Drug Discov (2006) 6.15
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol (2004) 1.38
Adenosine receptors and cancer. Handb Exp Pharmacol (2009) 1.14
Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia (2009) 1.07
Tumor necrosis factor alpha-induced apoptosis in astrocytes is prevented by the activation of P2Y6, but not P2Y4 nucleotide receptors. Biochem Pharmacol (2003) 1.04
Functional selectivity of adenosine receptor ligands. Purinergic Signal (2011) 0.93
A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation. Mol Pharmacol (2002) 0.91
Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A₃ adenosine receptor. Purinergic Signal (2006) 0.83
Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. J Cancer Res Clin Oncol (2011) 0.83
Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (1992) 12.92
Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell (1994) 7.23
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A (1985) 3.15
The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem (1993) 2.66
Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med (1996) 2.65
Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol (1995) 2.62
Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science (1998) 2.51
Activation of Akt/protein kinase B by G protein-coupled receptors. A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinasegamma. J Biol Chem (1998) 2.20
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. Evidence for a novel adenosine receptor. J Biol Chem (1990) 1.95
Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci (1994) 1.87
Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci (1998) 1.79
Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nat Med (1999) 1.73
Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. J Clin Invest (1996) 1.57
G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol Pharmacol (1995) 1.40
A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat. Br J Pharmacol (1995) 1.33
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1998) 1.32
Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications. Bioorg Med Chem Lett (2001) 1.26
Mast cell degranulation following adenosine A3 receptor activation in rats. Eur J Pharmacol (1996) 1.25
Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Biochem Biophys Res Commun (1996) 1.23
The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem Biophys Res Commun (1997) 1.10
p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res (2000) 1.06
Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist. Exp Cell Res (1998) 1.03
Activation of the A3 adenosine receptor affects cell cycle progression and cell growth. Naunyn Schmiedebergs Arch Pharmacol (2000) 1.02
Induction of apoptosis in rat cardiocytes by A3 adenosine receptor activation and its suppression by isoproterenol. Exp Cell Res (2000) 1.00
Fas antigen-mediated apoptosis in human granulosa/luteal cells. Biol Reprod (1995) 0.97
Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries. J Biol Chem (1996) 0.96
Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem Biophys Res Commun (1997) 0.96
Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur J Pharmacol (1999) 0.94
The effects of adenosine A3 receptor stimulation on seizures in mice. Eur J Pharmacol (1995) 0.93
Relative importance of adenosine A1 and A3 receptors in mediating physiological or pharmacological protection from ischemic myocardial injury in the rabbit heart. J Mol Cell Cardiol (1998) 0.93
Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ (1998) 0.92
Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int (1998) 0.91
Apoptosis and pathogenesis of viral hepatitis C--an update. In Vivo (2000) 0.84
A novel adenoviral vector expressing human Fas/CD95/APO-1 enhances p53-mediated apoptosis. Cell Death Differ (1999) 0.81
Flow cytometric evaluation of fas expression in relation to response and resistance to anthracyclines in leukemic cells. Cytometry (2000) 0.77
Lack of correlation in JNK activation and p53-dependent Fas expression induced by apoptotic stimuli. Biochem Biophys Res Commun (1999) 0.77
Structure of an agonist-bound human A2A adenosine receptor. Science (2011) 6.21
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev (2006) 5.28
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature (2007) 3.78
Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med (2003) 3.71
New insights into the pathoanatomy of diabetic macular edema: angiographic patterns and optical coherence tomography. Retina (2012) 3.30
Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc (2008) 2.80
Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci (2003) 2.37
The obesity epidemic and future emergency responders. Obesity (Silver Spring) (2009) 2.28
Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem (2004) 2.15
Efficient propagation of single cells Accutase-dissociated human embryonic stem cells. Mol Reprod Dev (2008) 2.12
Dynamics of receptor/G protein coupling in living cells. EMBO J (2005) 2.06
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J Med Chem (2002) 1.97
Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood (2005) 1.84
Determination of onset of sexual maturation and mating behavior by melanocortin receptor 4 polymorphisms. Curr Biol (2010) 1.82
N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. Biochem Pharmacol (2003) 1.82
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem (2002) 1.77
Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. Pharmacol Rev (2012) 1.73
Structure-based discovery of A2A adenosine receptor ligands. J Med Chem (2010) 1.71
Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem (2003) 1.70
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology (2010) 1.70
2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem (2003) 1.57
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem (2005) 1.54
Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta (2010) 1.53
Gs activation is time-limiting in initiating receptor-mediated signaling. J Biol Chem (2006) 1.52
2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. Br J Pharmacol (2002) 1.52
Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress. Mol Endocrinol (2008) 1.51
MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther (2005) 1.51
Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol (2002) 1.49
Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors. Trends Pharmacol Sci (2008) 1.46
Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. Mol Pharmacol (2003) 1.46
Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today (2011) 1.44
Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem (2002) 1.44
Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. J Med Chem (2005) 1.43
Molecular Architecture of G Protein-Coupled Receptors. Drug Dev Res (1996) 1.39
Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. J Med Chem (2009) 1.38
Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol (2004) 1.38
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res (2003) 1.35
Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg Med Chem (2004) 1.34
Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury. Am J Physiol Heart Circ Physiol (2007) 1.31
The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis (2006) 1.31
Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther (2004) 1.31
Conformational changes involved in G-protein-coupled-receptor activation. Trends Pharmacol Sci (2008) 1.29
Manipulation of dendritic cell function by viruses. Curr Opin Microbiol (2010) 1.29
Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. J Med Chem (2006) 1.28
Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart. Am J Physiol Heart Circ Physiol (2002) 1.27
Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists. J Med Chem (2002) 1.26
Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci U S A (2004) 1.25
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. J Med Chem (2003) 1.25
Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol (2004) 1.25
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor. J Med Chem (2006) 1.25
Rapid identification of functionally critical amino acids in a G protein-coupled receptor. Nat Methods (2007) 1.24
Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem (2012) 1.23
Keynote review: allosterism in membrane receptors. Drug Discov Today (2006) 1.22
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol (2009) 1.22
"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem (2005) 1.21
Trimanganese complexes bearing bidentate nitrogen ligands as a highly efficient catalyst precursor in the epoxidation of alkenes. J Org Chem (2006) 1.21
Identification of lineage relationships and novel markers of blood and skin human dendritic cells. J Immunol (2012) 1.21
Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. Mol Pharmacol (2009) 1.20
Controlling murine and rat chronic pain through A3 adenosine receptor activation. FASEB J (2012) 1.20
Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J Biol Chem (2010) 1.20
Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells. Mol Cell Biol (2008) 1.20
BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene (2005) 1.19
Emerging adenosine receptor agonists. Expert Opin Emerg Drugs (2007) 1.19
Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. J Med Chem (2007) 1.18
Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Res Rev (2006) 1.18
Paraffin embedding tissue samples for sectioning. CSH Protoc (2008) 1.18
Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. Bioconjug Chem (2008) 1.17
The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr Eye Res (2005) 1.17
Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M(3) muscarinic acetylcholine receptor. J Biol Chem (2005) 1.17
CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochem Pharmacol (2005) 1.17
GPCR and G proteins: drug efficacy and activation in live cells. Mol Endocrinol (2009) 1.16
Structural determinants of efficacy at A3 adenosine receptors: modification of the ribose moiety. Biochem Pharmacol (2004) 1.16
Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem (2008) 1.16
Activity of Novel Adenine Nucleotide Derivatives as Agonists and Antagonists at Recombinant Rat P2X Receptors. Drug Dev Res (2000) 1.16
Molecular basis of partial agonism at the neurotransmitter alpha2A-adrenergic receptor and Gi-protein heterotrimer. J Biol Chem (2006) 1.14
UDP is a competitive antagonist at the human P2Y14 receptor. J Pharmacol Exp Ther (2008) 1.13
Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. Bioconjug Chem (2008) 1.13
Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res (2010) 1.12
Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.12
Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor. J Med Chem (2007) 1.12
A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates. FASEB J (2012) 1.11
Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol (2002) 1.11
2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. Biochem Pharmacol (2004) 1.11
P2Y6 nucleotide receptor activates PKC to protect 1321N1 astrocytoma cells against tumor necrosis factor-induced apoptosis. Cell Mol Neurobiol (2003) 1.11
Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system. J Med Chem (2009) 1.10
Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chem Commun (Camb) (2003) 1.10
NFAT5 induction and its role in hyperosmolar stressed human limbal epithelial cells. Invest Ophthalmol Vis Sci (2008) 1.10
UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation. Biochem Pharmacol (2009) 1.10
Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety. Bioorg Med Chem Lett (2005) 1.09
Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem (2008) 1.08
[32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. Br J Pharmacol (2006) 1.07
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett (2008) 1.07
Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell Mol Neurobiol (2003) 1.07
Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists. Bioorg Med Chem (2004) 1.07